INT52403

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1994
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 1.79
Pain Relevance 3.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (HTR2B) cytoplasm (HTR2B) signal transducer activity (HTR2B)
Anatomy Link Frequency
MT2 1
brain 1
HTR2B (Homo sapiens)
Pain Link Frequency Relevance Heat
Serotonin 13 100.00 Very High Very High Very High
5HT 10 100.00 Very High Very High Very High
Desipramine 6 99.96 Very High Very High Very High
sSRI 25 99.80 Very High Very High Very High
Migraine 18 99.42 Very High Very High Very High
Potency 4 98.90 Very High Very High Very High
fluoxetine 27 96.84 Very High Very High Very High
depression 49 96.12 Very High Very High Very High
antidepressant 42 89.00 High High
headache 17 75.00 Quite High
Disease Link Frequency Relevance Heat
Migraine Disorders 14 99.42 Very High Very High Very High
Headache 15 97.68 Very High Very High Very High
Eating Disorder 4 97.16 Very High Very High Very High
Anxiety Disorder 22 96.48 Very High Very High Very High
Depression 51 96.12 Very High Very High Very High
Disease 1 75.00 Quite High
Recurrence 20 58.80 Quite High
Vomiting 12 5.00 Very Low Very Low Very Low
Sleep Disorders 11 5.00 Very Low Very Low Very Low
Dizziness 8 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Furthermore, the potency of drugs used in migraine prophylaxis to stimulate or inhibit 5-HT2B or 5-HT2C receptor-mediated potency of drugs used in migraine prophylaxis to stimulate or inhibit 5-HT2B or 5-HT2C receptor-mediated phosphatidyl inositol hydrolysis was measured.
Negative_regulation (inhibit) of 5-HT2B associated with migraine and potency
1) Confidence 0.42 Published 1996 Journal Eur. J. Neurosci. Section Abstract Doc Link 8743744 Disease Relevance 0.51 Pain Relevance 0.86
Furthermore, the potency of drugs used in migraine prophylaxis to stimulate or inhibit 5-HT2B or 5-HT2C receptor-mediated potency of drugs used in migraine prophylaxis to stimulate or inhibit 5-HT2B or 5-HT2C receptor-mediated phosphatidyl inositol hydrolysis was measured.
Negative_regulation (inhibit) of 5-HT2B associated with migraine and potency
2) Confidence 0.42 Published 1996 Journal Eur. J. Neurosci. Section Abstract Doc Link 8743744 Disease Relevance 0.50 Pain Relevance 0.81
In the present study the possibility that SSRI's act by desensitizing 5-HT2C/5-HT2B receptors was assessed using a putative in vivo model of 5-HT2C/5-HT2B receptor function, mCPP-induced hypolocomotion. mCPP (2, 4 and 6 mg/kg i.p. 20 min pretest) reduced locomotion and rears in rats treated acutely or chronically with saline.
Negative_regulation (desensitizing) of 5-HT2B associated with ssri
3) Confidence 0.41 Published 1994 Journal Neuropharmacology Section Abstract Doc Link 7760981 Disease Relevance 0.48 Pain Relevance 0.55
As chronic fluoxetine and paroxetine did not reduce brain mCPP levels (determined by HPLC 30 min after 4 mg/kg i.p.) the results suggest that chronic SSRI's, but not desipramine, reduce 5-HT2C/5-HT2B receptor responsivity.
Negative_regulation (reduce) of 5-HT2B in brain associated with desipramine, ssri and fluoxetine
4) Confidence 0.18 Published 1994 Journal Neuropharmacology Section Abstract Doc Link 7760981 Disease Relevance 0 Pain Relevance 0.71
It stimulates the activity of melatonin MT1 and MT2 receptors and inhibits the activity of serotonin 5HT-2C receptor subtypes.
Negative_regulation (inhibits) of 5HT-2C receptor in MT2 associated with 5ht and serotonin
5) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Abstract Doc Link PMC2785860 Disease Relevance 0.30 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox